🧫
Generation of Aβ-specific Tregs using CRISPR-Cas9
active
experiment
Created: 2026-04-10T22:51:28
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-c46efe01-e52c-4d3e-ac1f-09ab71cbd2c6
🧫 Experiment Protocol
ExploratoryAlzheimer's diseaseengineered Tregsproposed
This experiment involved engineering regulatory T cells (Tregs) to express amyloid-beta (Aβ) specific T cell receptors (TCRAβ). The process used CRISPR-Cas9 technology to knock out the endogenous TCR in Tregs, followed by incorporation of a transgenic TCRAβ that was originally identified from Aβ-reactive effector T cell monoclones. The engineered TCRAβ-Tregs were validated for antigen specificity using MHC-Aβ-tetramer staining. This represents a novel approach to create disease-specific immunotherapy by conferring antigen specificity to naturally immunosuppressive Tregs, potentially allowing them to specifically target brain regions affected by Alzheimer's disease pathology while maintaining their regulatory functions.
PRIMARY OUTCOME
Generation of antigen-specific Tregs
EXPECTED OUTCOMES
Tregs expressing Aβ-specific TCR with maintained regulatory function
SUCCESS CRITERIA
Positive MHC-Aβ-tetramer staining confirming antigen specificity
PROTOCOL
CRISPR-Cas9 knockout of endogenous TCR followed by transgenic TCRAβ incorporation, validated by MHC-Aβ-tetramer staining
LINKED HYPOTHESES
Source: PMID 38111016 ↗
🧫 Experiment Extras
PATHWAY
T cell receptor signaling, regulatory T cell function
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.